VivoSeq
Immunology

Cryoglobulinemia

7

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Cryoglobulinemia is an early-stage landscape with 7 programs across 3 companies. The most active players are Iovance Biotherapeutics, Inc., Roche, Glaxo Dba Glaxosmithkline.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

50/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

1 program

Phase 1Roche logo

Roche

2 programs

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Monoclonal antibody457%
Small molecule229%
Protein / enzyme114%

Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

5

clinical trials

Unknown status1 · 20%
Terminated1 · 20%
Completed1 · 20%
Recruiting1 · 20%
Not yet recruiting1 · 20%

Clinical Trials

Trial Activity

Isatuximab in Type I Cryoglobulinemia
Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05114109·21 enrolled
Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis
Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02556866·14 enrolled
Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia
Completed·HHospices Civils de Lyon·N/A·NCT03342261·47 enrolled
Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04629144·48 enrolled
A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT07268521·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)